Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Subcutaneous Tanezumab in Osteoarthritis
NCT00994890Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2009
- Primary completion
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tanezumab in osteoarthritis (OA), sponsored by Pfizer. Started Nov 2009; status: terminated.
02
Drugs
tanezumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00994890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00994890.